Antibodies that potently neutralize RSV and uses thereof
AssigneeHumabs Biomed SA
InventorDavide Corti
Life of this patent
Estimating the term…
Abstract
The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both group A and group B RSV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV infection and group A and group B RSV co-infection.
Claims20
A method of reducing RSV group A or group B RSV infection, or lowering the risk of group A RSV or group B RSV infection, comprising:
- administering to a subject in need thereof, a therapeutically effective amount of an antibody, or an antigen binding fragment thereof comprising:
- (i) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 1-6, respectively;
- (ii) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 17-22, respectively;
- (iii) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 33-38, respectively;
- or (iv) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 49-54, respectively.
A method of treatment or attenuation of group A RSV or group B RSV infection comprising:
- administering to a subject in need thereof, a therapeutically effective amount of an antibody, or an antigen binding fragment thereof, comprising:
- (i) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 1-6, respectively;
- (ii) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 17-22, respectively;
- (iii) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 33-38, respectively;
- or (iv) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 49-54, respectively.
A method of treatment or attenuation of group A RSV or group B RSV infection comprising:
- administering to a subject in need thereof, a therapeutically effective amount of a nucleic acid comprising a polynucleotide encoding an antibody, or an antigen binding fragment thereof, comprising:
- (i) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 1-6, respectively;
- (ii) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 17-22, respectively;
- (iii) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 33-38, respectively;
- or (iv) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 49-54, respectively.
A method of treatment or attenuation of group A RSV or group B RSV infection comprising:
- administering to a subject in need thereof, a therapeutically effective amount of a cell expressing an antibody, or an antigen binding fragment thereof, comprising:
- (i) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 1-6, respectively;
- (ii) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 17-22, respectively;
- (iii) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 33-38, respectively;
- or (iv) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 49-54, respectively.
A method of treatment or attenuation of group A RSV or group B RSV infection comprising:
- administering to a subject in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising
- (a) an antibody, or an antigen binding fragment thereof, comprising:
- (i) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 1-6, respectively;
- (ii) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 17-22, respectively;
- (iii) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 33-38, respectively;
- or (iv) heavy chain CDR1, CDR2, and CDR3 amino acid sequences and light chain CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs:
- 49-54, respectively;
- and
- (b) a pharmaceutically acceptable excipient, diluent or carrier.
Dependencies are inferred from the claim text.